Histone deacetylase inhibitor trichostatin a ameliorated endotoxin-induced neuroinflammation and cognitive dysfunction

Mediators of Inflammation

Volumn 2015, Issue , 2015, Pages

  Hsing, Chung Hsi ^a,b   Hung, Shih Kai ^c,d   Chen, Yeong Chang ^a   Wei, Tsui Shan ^a   Sun, Ding Ping ^a   Wang, Jhi Joung ^a   Yeh, Ching Hua ^e  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^d TZU CHI UNIVERSITY   (Taiwan)

^e DA YEH UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ESCHERICHIA COLI LIPOPOLYSACCHARIDE; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 5; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRICHOSTATIN A; ANTIINFLAMMATORY AGENT; ENDOTOXIN; HDAC2 PROTEIN, MOUSE; HDAC5 PROTEIN, HUMAN; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR;

ADULT; ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BEHAVIOR CHANGE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; FLUID INTAKE; FOOD INTAKE; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MICROGLIA; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSYCHOSOCIAL WITHDRAWAL; SUCROSE PREFERENCE TEST; WEIGHT REDUCTION; ANIMAL; BRAIN; CELL LINE; CHEMICALLY INDUCED; COGNITION DISORDERS; DRUG EFFECTS; GENETICS; METABOLISM;

ESCHERICHIA COLI; MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN; CELL LINE; COGNITION; COGNITION DISORDERS; ENDOTOXINS; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HYDROXAMIC ACIDS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTERLEUKIN-1BETA; LIPOPOLYSACCHARIDES; LOCOMOTION; MICE; MICROGLIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84939124602     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2015/163140     Document Type: Article

References (40)

1. Y. Xu, J. Yan, P. Zhou, et al., "Neurotransmitter receptors and cognitive dysfunction in Alzheimers disease and Parkinsons disease," Progress in Neurobiology, vol. 97, no. 1, pp. 1-13, 2012.
2. Y. Wan, J. Xu, D. Ma, Y. Zeng, M. Cibelli, and M. Maze, "Postoperative impairment of cognitive function in rats: a possible role for cytokine-mediated inflammation in the hippocampus," Anesthesiology, vol. 106, no. 3, pp. 436-443, 2007.
3. N. Terrando, C. Monaco, D. Ma, B. M. J. Foxwell, M. Feldmannc, and M. Maze, "Tumor necrosis factor-alpha triggers a cytokine cascade yielding postoperative cognitive decline," Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 47, pp. 20518-20522, 2010.
4. J. C. M. Schlachetzki and M. Hüll, "Microglial activation in Alzheimers disease," Current Alzheimer Research, vol. 6, no. 6, pp. 554-563, 2009.
5. M. C. Morganti-Kossmann, L. Satgunaseelan, N. Bye, and T. Kossmann, "Modulation of immune response by head injury," Injury, vol. 38, no. 12, pp. 1392-1400, 2007.
6. K. W. Kelley, R. M. Bluthé, R. Dantzer, et al., "Cytokineinduced sickness behavior," Brain, Behavior, and Immunity, vol. 17, supplement 1, pp. S112-S118, 2003.
7. R. Dantzer and K. W. Kelley, "Twenty years of research on cytokine-induced sickness behavior," Brain, Behavior, and Immunity, vol. 21, no. 2, pp. 153-160, 2007.
8. L. L. Skalisz, V. Beijamini, S. L. Joca, M. A. B. F. Vital, C. Da Cunha, and R. Andreatini, "Evaluation of the face validity of reserpine administration as an animal model of depression-Parkinsons disease association," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 26, no. 5, pp. 879-883, 2002.
9. F. Frenois, M. Moreau, J. OConnor, et al., "Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior," Psychoneuroendocrinology, vol. 32, no. 5, pp. 516-531, 2007.
10. J. Abraham, S. Jang, J. P. Godbout, et al., "Aging sensitizes mice to behavioral deficits induced by central HIV-1 gp120," Neurobiology of Aging, vol. 29, no. 4, pp. 614-621, 2008.
11. T. K. S. Craft and A. C. DeVries, "Role of IL-1 in poststroke depressive-like behavior in mice," Biological Psychiatry, vol. 60, no. 8, pp. 812-818, 2006.
12. S. Layé, P. Parnet, E. Goujon, and R. Dantzer, "Peripheral administration of lipopolysaccharide induces the expression of cytokine transcripts in the brain and pituitary of mice," Molecular Brain Research, vol. 27, no. 1, pp. 157-162, 1994.
13. R. Dantzer, J. C. OConnor, G. G. Freund, R. W. Johnson, and K. W. Kelley, "From inflammation to sickness and depression: when the immune systemsubjugates the brain," Nature Reviews Neuroscience, vol. 9, no. 1, pp. 46-56, 2008.
14. J. Chen, J. B. Buchanan, N. L. Sparkman, J. P. Godbout, G. G. Freund, and R. W. Johnson, "Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system," Brain, Behavior, and Immunity, vol. 22, no. 3, pp. 301-311, 2008.
15. Y. Huang, C. J. Henry, R. Dantzer, R. W. Johnson, and J. P. Godbout, "Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide," Neurobiology of Aging, vol. 29, no. 11, pp. 1744-1753, 2008.
16. J. P. Godbout, M. Moreau, J. Lestage, et al., "Aging exacerbates depressive-like behavior in mice in response to activation of the peripheral innate immune system," Neuropsychopharmacology, vol. 33, no. 10, pp. 2341-2351, 2008.
17. G. A. Garden and T. Möller, "Microglia biology in health and disease," Journal of Neuroimmune Pharmacology, vol. 1, no. 2, pp. 127-137, 2006.
18. A. D. Kraft and G. J. Harry, "Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity," International Journal of Environmental Research and Public Health, vol. 8, no. 7, pp. 2980-3018, 2011.
19. K. Saijo and C. K. Glass, "Microglial cell origin and phenotypes in health and disease," Nature Reviews Immunology, vol. 11, no. 11, pp. 775-787, 2011.
20. A. Fischer, F. Sananbenesi, A. Mungenast, and L.-H. Tsai, "Targeting the correct HDAC(s) to treat cognitive disorders," Trends in Pharmacological Sciences, vol. 31, no. 12, pp. 605-617, 2010.
21. C. L. Peterson and M.-A. Laniel, "Histones and histone modifications," Current Biology, vol. 14, no. 14, pp. R546-R551, 2004.
22. V. Kannan, N. Brouwer, U.-K. Hanisch, T. Regen, B. J. L. Eggen, and H. W. G. M. Boddeke, "Histone deacetylase inhibitors suppress immune activation in primary mouse microglia," Journal of Neuroscience Research, vol. 91, no. 9, pp. 1133-1142, 2013.
23. S. J. Shuttleworth, S. G. Bailey, and P. A. Townsend, "Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases," Current Drug Targets, vol. 11, no. 11, pp. 1430-1438, 2010.
24. H.-S. Suh, S. Choi, P. Khattar, N. Choi, and S. C. Lee, "Histone deacetylase inhibitors suppress the expression of inflammatory and innate immune response genes in human microglia and astrocytes," Journal of Neuroimmune Pharmacology, vol. 5, no. 4, pp. 521-532, 2010.
25. M. A. Halili, M. R. Andrews, L. I. Labzin, et al., "Differential effects of selective HDAC inhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS," Journal of Leukocyte Biology, vol. 87, no. 6, pp. 1103-1114, 2010.
26. H. J. Kim, M. Rowe, M. Ren, J. S. Hong, P. S. Chen, and D. M. Chuang, "Histone deacetylase inhibitors exhibit antiinflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action," Journal of Pharmacology and Experimental Therapeutics, vol. 321, no. 3, pp. 892-901, 2007.
27. I. M. Adcock, "HDAC inhibitors as anti-inflammatory agents," British Journal of Pharmacology, vol. 150, no. 7, pp. 829-831, 2007.
28. J.-L. Bret-Dibat and R. Dantzer, "Cholecystokinin receptors do not mediate the suppression of food-motivated behavior by lipopolysaccharide and interleukin-1 beta in mice," Physiology and Behavior, vol. 69, no. 3, pp. 325-331, 2000.
29. J. M. Levenson, K. J. ORiordan, K. D. Brown, M. A. Trinh, D. L. Molfese, and J. D. Sweatt, "Regulation of histone acetylation during memory formation in the hippocampus," The Journal of Biological Chemistry, vol. 279, no. 39, pp. 40545-40559, 2004.
30. J.-S. Guan, S. J. Haggarty, E. Giacometti, et al., "HDAC2 negatively regulatesmemory formation and synaptic plasticity," Nature, vol. 459, no. 7243, pp. 55-60, 2009.
31. C. L. Benn, R. Butler, L. Mariner, et al., "Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntingtons disease," PLoS ONE, vol. 4, no. 6, Article ID e5747, 2009.
32. N. M. Tsankova, O. Berton, W. Renthal, A. Kumar, R. L. Neve, and E. J. Nestler, "Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action," Nature Neuroscience, vol. 9, no. 4, pp. 519-525, 2006.
33. S. Peleg, F. Sananbenesi, A. Zovoilis, et al., "Altered histone acetylation is associated with age-dependentmemory impairment in mice," Science, vol. 328, no. 5979, pp. 753-756, 2010.
34. J. M. Rubio-Perez and J. M. Morillas-Ruiz, "A review: inflammatory process in Alzheimers disease, role of cytokines," The Scientific World Journal, vol. 2012, Article ID 756357, 15 pages, 2012.
35. A.-M. van Dam, M. Brouns, S. Louisse, and F. Berkenbosch, "Appearance of interleukin-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: a pathway for the induction of non-specific symptoms of sickness?" Brain Research, vol. 588, no. 2, pp. 291-296, 1992.
36. R. Dantzer, "Cytokine-induced sickness behavior: where do we stand?" Brain, Behavior, and Immunity, vol. 15, no. 1, pp. 7-24, 2001.
37. J. C. OConnor, M. A. Lawson, C. André, et al., "Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2, 3-dioxygenase activation in mice," Molecular Psychiatry, vol. 14, no. 5, pp. 511-522, 2009.
38. D. R. Walkinshaw and X.-J. Yang, "Histone deacetylase inhibitors as novel anticancer therapeutics," Current Oncology, vol. 15, no. 5, pp. 70-76, 2008.
39. K. Iwata, K. Tomita, H. Sano, Y. Fujii, A. Yamasaki, and E. Shimizu, "TrichostatinA, a histone deacetylase inhibitor, downregulates interleukin-12 transcription in SV-40-transformed lung epithelial cells," Cellular Immunology, vol. 218, no. 1-2, pp. 26-33, 2002.
40. R. Glauben, A. Batra, I. Fedke, et al., "Histone hyperacetylation is associated with amelioration of experimental colitis in mice," Journal of Immunology, vol. 176, no. 8, pp. 5015-5022, 2006.